Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chimera Antigen Receptor (CAR)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT07250269
What this trial is testing

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Who this might be right for
Relapsed/Refractory AL Amyloidosis
Gracell Biotechnologies (Shanghai) Co., Ltd. 9
Testing effectiveness (Phase 2)Looking for participantsNCT05243212
What this trial is testing

Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma

Who this might be right for
Multiple MyelomaRelapse Multiple Myeloma
Sheba Medical Center 75
Testing effectiveness (Phase 2)Looking for participantsNCT07072494
What this trial is testing

CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study

Who this might be right for
Acute Lymphoblastic Leukemia
Zhujiang Hospital 30
Early research (Phase 1)Looking for participantsNCT05298995
What this trial is testing

GD2-CAR T Cells for Pediatric Brain Tumours

Who this might be right for
Brain Tumor, PediatricMedulloblastoma, ChildhoodEmbryonal Tumor+4 more
Bambino Gesù Hospital and Research Institute 54
Not applicableLooking for participantsNCT06717022
What this trial is testing

A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors

Who this might be right for
Mesothelin Positive Tumors
Tianjin Medical University Cancer Institute and Hospital 24
Early research (Phase 1)Looking for participantsNCT04892277
What this trial is testing

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic Lymphoma+5 more
Mayo Clinic 25
Very early researchUnknownNCT04626765
What this trial is testing

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Who this might be right for
Childhood Acute Lymphoblastic Leukemia
Hebei Senlang Biotechnology Inc., Ltd. 50
Early research (Phase 1)Study completedNCT04088864
What this trial is testing

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

Who this might be right for
B Cell LymphomaAcute Lymphoblastic Leukemia, PediatricLymphoma
Kara Lynn Davis 10
Early research (Phase 1)UnknownNCT03423992
What this trial is testing

Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas

Who this might be right for
GliomaMalignant Glioma of BrainRecurrence Tumor
Xuanwu Hospital, Beijing 100
Testing effectiveness (Phase 2)Looking for participantsNCT04792489
What this trial is testing

DALY II USA/ MB-CART2019.1 for DLBCL

Who this might be right for
Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed Diffuse Large B Cell LymphomaHigh Grade B-cell Lymphoma (HGBCL)+6 more
Miltenyi Biomedicine GmbH 315
Early research (Phase 1)UnknownNCT02842138
What this trial is testing

Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma

Who this might be right for
B-cell Lymphoma
Peking University 25
Testing effectiveness (Phase 2)Looking for participantsNCT05521802
What this trial is testing

C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Shanghai AbelZeta Ltd. 92
Early research (Phase 1)WithdrawnNCT06003179
What this trial is testing

Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah

Who this might be right for
Lymphoma, Large B-Cell, Diffuse
University Health Network, Toronto
Early research (Phase 1)UnknownNCT04381741
What this trial is testing

CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma

Who this might be right for
Diffuse Large B-cell Lymphoma
Second Affiliated Hospital, Zhejiang University, School of Medicine 24
Early research (Phase 1)Ended earlyNCT02706405
What this trial is testing

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma+3 more
Fred Hutchinson Cancer Center 30
Not applicableWithdrawnNCT05416554
What this trial is testing

Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford

Who this might be right for
Non Hodgkin Lymphoma
Stanford University
Not applicableStudy completedNCT04169022
What this trial is testing

AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells

Who this might be right for
Acute Myeloid Leukemia
Centre Hospitalier Universitaire de Besancon 86
Testing effectiveness (Phase 2)UnknownNCT02839954
What this trial is testing

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

Who this might be right for
Hepatocellular CarcinomaNon-small Cell Lung CancerPancreatic Carcinoma+4 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Testing effectiveness (Phase 2)Looking for participantsNCT06486051
What this trial is testing

Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma

Who this might be right for
Large B-cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-cell Lymphoma (PMBCL)+1 more
Malaghan Institute of Medical Research 60
Early research (Phase 1)WithdrawnNCT05037669
What this trial is testing

Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma

Who this might be right for
Acute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
University of Pennsylvania
Next Page